search
Back to results

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
BT-001
Physician-guided Standard of Care for type 2 diabetes
Sponsored by
Better Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Between 18 and 75 years old, inclusive at the time of signing the informed consent;
  2. Diagnosis of type 2 diabetes, according to the criteria of the American Diabetes Association (ADA), and confirmed at the initial eligibility screening;
  3. Body Mass Index ≥25 kg/m2;
  4. Possesses a smartphone (iPhone or Android only) capable of running the smartphone applications (Apps) used in the study;
  5. Has had no change in the last 4 months prior to randomization (3 months prior to initial screening plus 30-day run-in screening period) in antihyperglycemic medications;
  6. Has a current HbA1c level >7%, as determined by both screening assessments;
  7. Willing to use an FDA approved glucometer for self-monitoring blood glucose throughout the study;
  8. Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

Exclusion Criteria

  1. Are unable to understand, consent to, or comply with the study protocol for any reason;
  2. Currently taking prandial (mealtime) insulin;
  3. Have self-reported measures, collected during screening interview, that reveal:

    1. An active eating disorder
    2. The taking of or planning to take (within the next 6 months):

    i. Oral steroids (planned, or within the past 3 months) ii. Chemotherapy (planned, or within the past 6 months) iii. Weight loss medications or iv. Atypical antipsychotic medications

    c. A change in antidepressant or anti-anxiety medication within the past 3 months;

    d. A history of bariatric surgery or planned bariatric surgery during the study;

    e. The current use of marijuana, cocaine, opioid painkillers, or other addictive substances;

    f. The current use of tobacco products or use of tobacco products within the past 6 months;

    g. The consumption of alcohol above defined thresholds:

    i. For women: more than 3 drinks in a single day, or more than 7 drinks per week and ii. For men: more than 4 drinks in a single day, or more than 14 drinks per week

    h. An unstable or life-threatening medical illness;

    i. Non-resolved, presumed or confirmed COVID-19 diagnosis prior to randomization or during primary study period;

    j. For women only: pregnant (or lactating) or having the intention of becoming pregnant during the time frame of the study.

  4. Has a current HbA1c level ≥11%, at the screening assessment;
  5. Concurrent enrollment in any other clinical trial;
  6. Is considered unreliable by the investigator, or having any condition which, in the opinion of the investigator, would not allow safe participation in the study.

Sites / Locations

  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site
  • Study Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

BT-001 + Standard of Care

Standard of Care

Arm Description

BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes

Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician

Outcomes

Primary Outcome Measures

The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups
Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.

Secondary Outcome Measures

The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups
Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.

Full Information

First Posted
May 7, 2021
Last Updated
September 26, 2023
Sponsor
Better Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT04886388
Brief Title
Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
Official Title
Open-Label, Randomized, Controlled, Parallel-Group Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
April 22, 2021 (Actual)
Primary Completion Date
March 9, 2022 (Actual)
Study Completion Date
September 27, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Better Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) compared to standard medical care in patients with type 2 diabetes.
Detailed Description
The study will utilize an open-label, randomized, parallel-group design to confirm and characterize the safety and efficacy of BT-001 used in addition to standard of care (SOC) when compared to SOC alone in patients with type 2 diabetes. The screening period will consist of a run-in during which time HbA1c will be assessed for confirmation of eligibility. Once confirmed to be eligible, patients will then be randomized 1:1 to the following groups: Investigational: One half of the participants will be treated with BT-001 plus SOC for 180 days; Control: One half of the participants will be treated with SOC alone for 180 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Open-Label, Randomized, Controlled
Masking
None (Open Label)
Allocation
Randomized
Enrollment
668 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BT-001 + Standard of Care
Arm Type
Experimental
Arm Description
BT-001 is a software program used with physician guidance, being investigated to improve glycemic control. Patients randomized to this arm of the study will interact with the BT-001 software program in addition to receiving Standard of Care for type 2 diabetes
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
Patients randomized to the Standard of Care arm will receive Standard of Care treatment for type 2 diabetes under the guidance of a physician
Intervention Type
Device
Intervention Name(s)
BT-001
Intervention Description
BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
Intervention Type
Other
Intervention Name(s)
Physician-guided Standard of Care for type 2 diabetes
Intervention Description
Current ADA Standard of Care Guidelines for type 2 diabetes
Primary Outcome Measure Information:
Title
The difference in the mean change from baseline in HbA1c at Day 90 between Intervention and Standard of Care groups
Description
Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.
Time Frame
Baseline and Day 90
Secondary Outcome Measure Information:
Title
The difference in the mean change from baseline in HbA1c at Day 180 between Intervention and Standard of Care groups
Description
Hemoglobin A1c (HbA1c) test measures the amount of blood sugar (glucose) attached to hemoglobin.
Time Frame
Baseline and Day 180

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Between 18 and 75 years old, inclusive at the time of signing the informed consent; Diagnosis of type 2 diabetes, according to the criteria of the American Diabetes Association (ADA), and confirmed at the initial eligibility screening; Body Mass Index ≥25 kg/m2; Possesses a smartphone (iPhone or Android only) capable of running the smartphone applications (Apps) used in the study; Has had no change in the last 4 months prior to randomization (3 months prior to initial screening plus 30-day run-in screening period) in antihyperglycemic medications; Has a current HbA1c level >7%, as determined by both screening assessments; Willing to use an FDA approved glucometer for self-monitoring blood glucose throughout the study; Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). Exclusion Criteria Are unable to understand, consent to, or comply with the study protocol for any reason; Currently taking prandial (mealtime) insulin; Have self-reported measures, collected during screening interview, that reveal: An active eating disorder The taking of or planning to take (within the next 6 months): i. Oral steroids (planned, or within the past 3 months) ii. Chemotherapy (planned, or within the past 6 months) iii. Weight loss medications or iv. Atypical antipsychotic medications c. A change in antidepressant or anti-anxiety medication within the past 3 months; d. A history of bariatric surgery or planned bariatric surgery during the study; e. The current use of marijuana, cocaine, opioid painkillers, or other addictive substances; f. The current use of tobacco products or use of tobacco products within the past 6 months; g. The consumption of alcohol above defined thresholds: i. For women: more than 3 drinks in a single day, or more than 7 drinks per week and ii. For men: more than 4 drinks in a single day, or more than 14 drinks per week h. An unstable or life-threatening medical illness; i. Non-resolved, presumed or confirmed COVID-19 diagnosis prior to randomization or during primary study period; j. For women only: pregnant (or lactating) or having the intention of becoming pregnant during the time frame of the study. Has a current HbA1c level ≥11%, at the screening assessment; Concurrent enrollment in any other clinical trial; Is considered unreliable by the investigator, or having any condition which, in the opinion of the investigator, would not allow safe participation in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Berman, MD
Organizational Affiliation
Better Therapeutics
Official's Role
Study Director
Facility Information:
Facility Name
Study Site
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
Facility Name
Study Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33101
Country
United States
Facility Name
Study Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30301
Country
United States
Facility Name
Study Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60007
Country
United States
Facility Name
Study Site
City
New York
State/Province
New York
ZIP/Postal Code
10001
Country
United States
Facility Name
Study Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77001
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

We'll reach out to this number within 24 hrs